Rani Therapeutics Changes Auditors

TL;DR

Rani Therapeutics swapped auditors from PwC to BDO USA, effective Sept 10.

AI Summary

Rani Therapeutics Holdings, Inc. announced on September 10, 2024, a change in its principal accounting firm. The company has dismissed PricewaterhouseCoopers LLP and engaged BDO USA, LLP as its new independent registered public accounting firm. This change is effective immediately.

Why It Matters

A change in auditors can sometimes signal underlying issues or a strategic shift within a company, potentially impacting investor confidence.

Risk Assessment

Risk Level: medium — Changes in accounting firms can sometimes precede or coincide with financial reporting issues or strategic shifts, warranting closer investor scrutiny.

Key Players & Entities

• Rani Therapeutics Holdings, Inc. (company) — Registrant
• PricewaterhouseCoopers LLP (company) — Former principal accounting firm
• BDO USA, LLP (company) — New independent registered public accounting firm
• September 10, 2024 (date) — Effective date of auditor change

FAQ

Key Financial Figures

• $0.0001 — tered Class A common stock, par value $0.0001 per share RANI The Nasdaq Stock Mar

Filing Documents

• rani-20240910.htm (8-K) — 44KB
• rani-ex16_1.htm (EX-16.1) — 4KB
• 0000950170-24-105509.txt ( ) — 164KB
• rani-20240910.xsd (EX-101.SCH) — 25KB
• rani-20240910_htm.xml (XML) — 5KB

01 Changes in Registrant's Certifying Accountant

Item 4.01 Changes in Registrant's Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm The Audit Committee of the Board of Directors (the "Audit Committee") of Rani Therapeutics Holdings, Inc. (the "Company") approved the dismissal of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm on September 10, 2024. The reports of EY on the Company's consolidated financial statements for the fiscal years ended December 31, 2022 and December 31, 2023 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that the report of the Company's consolidated financial statements for the year ended December 31, 2023 contained an explanatory paragraph which noted that there was substantial doubt about the Company's ability to continue as a going concern. During the fiscal years ended December 31, 2022 and December 31, 2023, and the subsequent interim period through September 10, 2024, there have been no "disagreements" (as defined in Item 304(a)(1)(iv) of Regulation S-K and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC")) with EY on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of EY would have caused EY to make reference there in its reports on the consolidated financing statements for such years. During the fiscal years ended December 31, 2022 and December 31, 2023, and subsequent interim period through September 10, 2024, there have been no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K). The Company provided EY with a copy of the disclosure it is making herein in response to Item 304(a) of Regulation S-K, and requested that EY furnish the Company with a copy of its letter addressed to the SEC, pursuant to Item 304(a)(3

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 16.1 Letter of Ernst & Young LLP to the Securities and Exchange Commission dated September 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Rani Therapeutics Holdings, Inc. Date: September 11, 2024 By: /s/ Svai Sanford Svai Sanford Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR